Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for goiter sufferers: blocking blood flow to nodules may ease breathing trouble

NCT ID NCT07360587

Symptom relief Sponsor: Université de Sherbrooke Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a procedure called thyroid artery embolization (TAE) for people with large thyroid nodules that press on the throat or windpipe, causing symptoms like trouble swallowing or breathing. The procedure blocks blood flow to the nodules to shrink them. Researchers will enroll 20 adults who cannot have or prefer not to have surgery. The goal is to see if TAE reduces nodule size and improves symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Thyroid artery embolization (a procedure that blocks blood flow to thyroid nodules)
What this could lead to
If it works, this could offer a non-surgical option to shrink thyroid nodules and relieve pressure on the throat and windpipe.
What could go wrong
This is a small, early study with only 20 people, so results may not apply to everyone. The procedure carries risks like bleeding, infection, or damage to nearby tissues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with compressive symptoms or significant tracheal or oesophageal compression at risk of causing symptoms attributed to a goiter AND * Ineligible for surgery/ablative treatments or preference for TAE over other treatments AND * TiRADS category 1, 2, 3 or 4 AND * Bethesda categories I or III on 2 different biopsies OR Bethesda II on one biopsy AND * Patient at least 18 years old. Exclusion Criteria: * Comorbidities precluding endovascular procedure OR * TiRADS category 5 OR * Bethesda categories IV, V, VI on biopsy OR * Refusal of the patient to participate OR * Uncontrolled severe hyperthyroidism OR * Minor patient.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Compressive goiter are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

goiter nodular goiter substernal goiter Thyroid Nodule

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thyroid nodules

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Universitaire de Sherbrooke

    RECRUITING

    Sherbrooke, Quebec, J1H5H3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.